Ciprofloxacin hydrogen sulfate | 853268-20-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Ciprofloxacin hydrogen sulfate
• 英文别名: 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;sulfuric acid
• CAS: 853268-20-9
• 化学式: C17H20FN3O7S
• 分子量: 429.4
• InChiKey: DQDUDUWTGSTECF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.93
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  156
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• Method of pulmonary administration of an agent
  申请人：Wong M.P. Frances

  公开号：US20050025822A1

  公开（公告）日：2005-02-03

  A method for administering a therapeutic or diagnostic agent to a subject is described. The method includes providing a suspension of liposomes comprised of one or more of vesicle-forming lipids selected from (i) a vesicle-forming lipid derivatized with a hydrophilic polymer and (ii) a neutral lipopolymer, said liposomes being associated with said therapeutic or diagnostic agent, forming an aerosol of said liposome suspension; and administering the aerosol to the subject by inhalation. The liposome formulation delivers intact liposomal particles to the respiratory tract of said subject to form a depot of therapeutic agent therein with no observable provocation of an immune response, as measured by neutrophil or macrophage cell count in the lung after administration.

  本文描述了一种向受试者施用治疗剂或诊断剂的方法。该方法包括提供由一种或多种囊泡形成脂质组成的脂质体悬浮液，这些囊泡形成脂质选自(i)用亲水性聚合物衍生的囊泡形成脂质和(ii)中性脂聚合物，所述脂质体与所述治疗剂或诊断剂相关联，形成所述脂质体悬浮液的气溶胶；以及通过吸入将气溶胶施用于受试者。脂质体制剂将完整的脂质体颗粒输送到所述受试者的呼吸道，在其中形成治疗剂储存库，而用药后通过肺部中性粒细胞或巨噬细胞计数测量，不会观察到引起免疫反应。
• LIPOSOME COMPOSITIONS FOR IMPROVED DRUG RETENTION
  申请人：Alza Corporation

  公开号：EP1176962A2

  公开（公告）日：2002-02-06
• METHOD OF PULMONARY ADMINISTRATION OF AN AGENT
  申请人：ALZA CORPORATION

  公开号：EP1628637A2

  公开（公告）日：2006-03-01
• [EN] LIPOSOME COMPOSITIONS FOR IMPROVED DRUG RETENTION<br/>[FR] COMPOSITION LIPOSOMIQUE POUR UNE RETENTION MEDICAMENTEUSE AMELIOREE
  申请人：ALZA CORP

  公开号：WO2000066126A2

  公开（公告）日：2000-11-09

  A liposome composition for enhanced retention of a quinolone compound, and in particular of a fluoroquinolone compound, is described. Entrapped in the liposomes is a polyanionic polymer effective to form a complex with the fluoroquinolone. A method of preparing the liposomes which includes a process for removal of unentrapped polyanionic polymer is also described.
• [EN] METHOD OF PULMONARY ADMINISTRATION OF AN AGENT<br/>[FR] METHODE D'ADMINISTRATION PULMONAIRE D'UN AGENT
  申请人：ALZA CORP

  公开号：WO2004110493A2

  公开（公告）日：2004-12-23

  A method for administering a therapeutic or diagnostic agent to a subject is described. The method includes providing a suspension of liposomes comprised of one or more of vesicle-forming lipids selected from (i) a vesicle-forming lipid derivatized with a hydrophilic polymer and (ii) a neutral lipopolymer, said liposomes being associated with said therapeutic or diagnostic agent, forming an aerosol of said liposome suspension; and administering the aerosol to the subject by inhalation. The liposome formulation delivers intact liposomal particles to the respiratory tract of said subject to form a depot of therapeutic agent therein with no observable provocation of an immune response, as measured by neutrophil or macrophage cell count in the lung after administration.